TBPH
Theravance Biopharma Inc
NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY
$16.52
-2.88% today
Updated 2026-05-11
Market cap
$876.78M
P/E ratio
7.63
P/S ratio
7.99x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$8 – $21
Volume
0.6M
Theravance Biopharma Inc (TBPH) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-83.43M | $-119.11M | $-120.96M | $-175.16M | $-168.86M | $-98.99M | $-201.05M | $-112.87M | $-238.20M | $-250.40M | $-207.86M | $-186.99M | $-27.00M | $-11.54M | $238.54M |
| Capital expenditures | $3.63M | $2.59M | $2.73M | $3.11M | $2.65M | $2.13M | $2.41M | $7.24M | $3.18M | $6.62M | $3.41M | $572000.00 | $2.49M | $332000.00 | $42000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $21.32M | $22.48M | $43.23M | $54.05M | $41.17M | $49.15M | $51.31M | $60.45M | $62.98M | $62.06M | $39.73M | $25.37M | $21.39M | $18.48M |
| Free cash flow | $-87.06M | $-121.70M | $-123.69M | $-178.26M | $-171.50M | $-101.12M | $-203.46M | $-120.11M | $-241.37M | $-257.02M | $-211.26M | $-187.56M | $-29.48M | $-11.87M | $238.50M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $385.06M | — | $802000.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $89.22M | $23.49M | $232.00M | $-255.73M | $289.04M | $-319.96M | $23.40M | $8.50M | $208.21M | — | — | — |